Role of TNFalpha in pulmonary pathophysiology.

Mukhopadhyay S, Hoidal JR, Mukherjee TK. · 2006

Read Role of TNFalpha in pulmonary pathophysiology. by Mukhopadhyay S, Hoidal JR, Mukherjee TK. (2006) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc1613248.txt.

Introduction

A swelling signal that helps fight germs can also wreck lungs. Mukhopadhyay, Hoidal, and Mukherjee reviewed TNFalpha in 2006, a potent immune messenger. At high levels it drives the inflammation behind many diseases.

In the lung, it is implicated in asthma, chronic bronchitis, COPD, acute lung injury, and its severe form ARDS. Beyond swelling, evidence ties it to direct cell killing. Drugs that curb its production or block its action already transformed care of some inflammatory diseases. Mukhopadhyay weighs their promise for lung disease against immune side effects. Blocking it, they add, must be weighed against its role in host defense.

Catalog record

CREATORMukhopadhyay S, Hoidal JR, Mukherjee TK.
YEAR2006
COLLECTIONPAPERS
FORMATTXT
FILE SIZE41 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC1613248

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Role of TNFα in pulmonary pathophysiology By Srirupa Mukhopadhyay, John R Hoidal, Tapan K Mukherjee Published in: Respiratory Research DOI: 10.1186/1465-9921-7-125 ABSTRACT Tumor necrosis factor alpha (TNFα) is the most widely studied pleiotropic cytokine of the TNF superfamily. In pathophysiological conditions, generation of TNFα at high levels leads to the development of inflammatory responses that are hallmarks of many diseases. Of the various pulmonary diseases, TNFα is implicated in asthma, chronic bronchitis (CB), chronic obstructive pulmonary disease (COPD), acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). In addition to its underlying role in the inflammatory events, there is increasing evidence for involvement of TNFα in the cytotoxicity. Thus, pharmacological agents that can either suppress the production of TNFα or block its biological actions may have potential therapeutic value against a wide variety of diseases. Despite some immunological side effects, anti-TNFα therapeutic strategies represent an important breakthrough in the treatment of inflammatory diseases and may have a role in pulmonary diseases characterized by inflammation and cell death. BACKGROUND TNFα is the most widely studied cytokine member of TNF super family. It is secreted by lipopolysaccharide stimulated macrophages and causes necrosis of tumor in vivo when injected into tumor bearing mice [1] and hence bearing the name tumor necrosis factor (TNF). Experimentally, TNFα causes cytolysis or cytostasis of certain transformed cells [2] being synergistic with gamma interferon in its cytotoxicity [3]. TNFα is produced by many different cell types. The main sources in vivo are stimulated monocytes, fibroblasts, and endothelial cells. Macrophages, T-cells, B-lymphocytes, granulocytes, smooth muscle cells, eosinophils, chondrocytes, osteoblasts, mast cells, glial cells, and keratinocytes also produce TNFα after stimulation. Glioblastoma cells constitutively produce TNFα and the factor can be detected also in the cerebrospinal fluid. Human milk also contains TNFα. Physiological stimuli for the synthesis of TNFα are IL-1, bacterial endotoxins, TNF, platelet derived growth factor (PDGF), and Oncostatin M. In fibroblasts the synthesis of TNFα is stimulated by IFNβ, TNFα, PDGF, and viral infections. In thymic stromal cells the synthesis of TNFα can be induced by neuronal growth factor (NGF). TNFα can also stimulate or inhibits its own synthesis, depending upon the cell type. In epithelial, endothelial, and fibroblastic cells secretion of TNFα is induced by IL-17. TNFα is a protein of 185 amino acids glycosylated at positions 73 and 172. It is synthesized as a precursor (inactive) protein of 212 amino acids. TNFα converting enzyme (TACE) mediates the cleavage of a membrane associated form of TNFα to inducing the formation of the bioactive soluble TNFα [4]. The secreted protein exists as a multimer of two, three or five noncovalently linked units, but shows a single 17-kDa band in SDS-PAGE under nonreducing conditions [5]. Monocytes express at least five different molecular forms of TNFα with molecular masses of 21.5–28 kDa. They mainly differ by post-translational alterations such as glycosylation and phosphorylation. TNFα is closely related to the 25-kDa protein of TNFβ (lymphotoxin) with around 30% amino acid sequence homology and sharing the same receptors and cellular actions [6]. TNFα mediated signaling plays an important role both in homeostasis and pathophysiology. ROLE OF TNFΑ IN PHYSIOLOGY AND PATHOPHYSIOLOGY Over the years it has become increasingly clear that TNFα signaling is a complex series of biological event that involves by at least 29 different tumor necrosis factor receptor (TNFR) family members [7,8]. Under physiological homeostatic conditions the biological functions of this family of cytokines encompasses beneficial and protective effects in both the innate immunity and haematopoiesis, and has a crucial role in organogenesis [7,8]. Members of the TNF super-family are also involved in signaling mechanisms of cellular proliferation, survival and apoptosis. In vivo, administration of bacterial lypopolysaccharide (LPS) induces high level of TNFα production in animal models and reproduces many common features of septic shock with severe pro-inflammatory reactions [9]. Furthermore, lethal septic shock does not occur in TNFα-deficient mice indicating an important contributory role of TNFα in this syndrome. A high level of TNFα is also observed in human subjects administered bacterial endotoxin [10]. These in vitro and in vivo studies indicate that high level generation of TNFα leads to the exacerbation of inflammatory and prooxidative responses that are important in the pathogenesis of many diseases, including various pulmonary disorders. Due to proinflammatory and prooxidative actions, TNFα complicates many diseases, the most important of which are atherosclerosis [11], rheumatoid arthritis [12], psoriasis [13], inflammatory bowel disease [14], Alzheimer's disease [15] and various pulmonary disorders. This review very precisely describes the roles of TNFα in various pulmonary diseases. MECHANISM OF ACTION OF TNFΑ IN PULMONARY PATHOLOGICAL CONSEQUENCES Inflammation is believed to be the key event of TNFα-dependent pathophysiological events. Deregulated recruitment of leukocytes and lymphocytes at the inflamed foci leads to injury. TNFα also depletes cellular glutathione (GSH), a cellular antioxidant [16]. Over-expression of TNFα in transgenic mice induces differential changes in redox status and glutathione-regulating enzymes [17] by depleting the total cellular glutathione levels. In vitro studies also demonstrate that TNFα depletes cellular GSH levels. Treatment of human pulmonary artery endothelial cells with TNFα decrease the GSH levels of the cells [18] and this depletion of glutathione enhances the endothelial cell susceptibility to oxygen toxicity [19]. The exact mechanism through which TNFα decreases the levels of glutathione in pulmonary tissues has not yet been fully determined. Both in vitro and in vivo studies show that TNFα stimulates the reactive oxygen species (ROS) generation from pulmonary and non-pulmonary tissues. Upon TNFα stimulation a high level generation of ROS is observed in human endothelial cells [20], and neutrophils [21]. Of the different cell types, ROS derived from neutrophils takes a very important role in TNFα-dependent alteration of pulmonary vasoreactivity [21]. However, another study observing the mechanism of adherence of neutrophil on human pulmonary microvascular endothelial cells show endothelial cells are the source of TNFα stimulated ROS not neutrophil [22]. Over the years it is generally assumed that in physiological homeostatic conditions most of the ROS generation takes place at the phagocytic cells such as macrophages or neutrophils and the ROS generation by nonphagocytic cells is a minor fraction to that of the phagocytic cells. At the subcellular level NADPH oxidase and mitochondria are the potential sites of TNFα-dependent ROS generation and subsequent oxidative stress in endothelial cells [23]. Recent studies indicate that NADPH oxidase and mitochondria are linked through a feedback mechanism [23]. Interestingly, a recent study has reported that the two sources ROS (mitochondria and NADPH oxidase) may have divergent pathways in endothelial cells: The mitochondrial pathway is suppressed by rotenone and appears to be directly involved in TNFα induced apoptosis by activating caspase 3. Another pathway is a membrane-dependent pathway that is associated with the NADPH oxidase and protects against TNFα-induced cell death by activation of small GTPase Rac1 (a component of NADPH oxidase) [24]. Thus, depending upon the type of stimulus and the levels of generation of ROS, cells may undergo either pro-survival or pro-apoptotic pathway in response to TNFα. During the course of ROS generation various adhesive and proinflammatory molecules are generated that are responsible for the complications of various inflammatory disorders [25] (Fig. 1). In short, induction of cellular inflammatory reactions, enhancement of oxidative stress and increased expression of various proinflammatory molecules altogether create

Read the complete text